Skip to content

Press Releases

View:
 
Press Releases
All Releases
May 12, 2014
Conference Call and Webcast Today, Monday, May 12, 2014 at 4:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density li...
May 6, 2014
Presentation and Webcast on Tuesday, May 13 at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced the Company will present at the 2014 Bank of America Merrill Lynch Healthcare Conference in La...
May 5, 2014
Conference Call and Webcast on Monday, May 12, 2014 at 4:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced that it will host a conference call and webcast to report first quarter 2014 operational and financial results...
May 1, 2014
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the company will deliver three posters featuring ETC-1002 Phase 2 clinical results at the 2014 Annual Scientific Sessions of the National Lipid Association in Orlando, Fla. The posters provide additional information fro...
Mar 24, 2014
Presentation and Webcast Held Friday, March 28 at 2:30 p.m. Eastern Time PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholester...
Mar 5, 2014
Conference Call and Webcast Today, Wednesday, March 5, 2014, at 4:30 p.m. Eastern Time PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-densit...
Feb 26, 2014
Conference Call and Webcast on Wednesday, March 5, 2014 at 4:30 p.m. Eastern Time PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipo...
Feb 13, 2014
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announc...
Jan 13, 2014
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announc...
Dec 23, 2013
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announc...
Nov 18, 2013
Data Presented in Oral Presentation Session at AHA's Scientific Sessions DALLAS & PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipo...
Nov 11, 2013
--Company To Also Webcast a Briefing of the Results-- PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) ...
Nov 6, 2013
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia,...
Nov 5, 2013
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announc...
Oct 30, 2013
Represents Company's First Clinical Study in Robust Phase 2b Program PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (L...
= add release to Briefcase